NCT06730581View on ClinicalTrials.gov

Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Gastric Cancer Adenocarcinoma MetastaticOvarian CancerBile Duct Cancer
Interventions
DRUG

Utidelone Capsule 60mg/m2/d

60mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone capsule 75mg/m2

75mg/m2/d, D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

DRUG

Utidelone Capsule

Dosing regimens were determined based on the results of gastric and ovarian cancer dosing regimens.D1-D5 for 5 consecutive days, every 21 days as a treatment cycle.

Sponsors
All Listed Sponsors
lead

Beijing Biostar Pharmaceuticals Co., Ltd.

INDUSTRY